# Eli Lilly and Company revenue entity: /record/eli-lilly.md predicate: revenue page: /record/eli-lilly/revenue as_of: 2026-11-09 cite: AsOf. "Eli Lilly and Company quarterly revenue: 24,397,000,000 United States dollar", as of 2026-09-30. Claim clm_E1B01E0405B5, https://asof.is/claim/clm_E1B01E0405B5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm. As of November 9, 2026, the latest revenue figure on the AsOf record for Eli Lilly and Company is $24.4 billion for the quarter ended September 30, 2026, from a primary source (sec.gov). Eli Lilly and Company's latest full-year revenue is $65.18 billion, dated December 31, 2025, from a primary source (sec.gov); the two periods are kept apart, never compared. 19 claims on Eli Lilly and Company's revenue, 1 open and 18 superseded, each dated and sourced; a replaced value is closed with an end date, never deleted. ## Latest revenue The newest figure for a shorter period, the quarter ended September 30, 2026: a quarterly_revenue claim, kept apart from the full-year series. Every quarterly revenue figure: /record/eli-lilly/quarterly_revenue.md - [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 24,397,000,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_E1B01E0405B5](/claim/clm_E1B01E0405B5.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm ## Latest full-year revenue What the record asserts on 2026-11-09. - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 65,179,000,000 United States dollar | valid 2025-12-31 to present | conf 0.95 | valid | [clm_C4636B99C62B](/claim/clm_C4636B99C62B.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.htm ## Every dated value One claim per line, oldest first. Superseded claims stay visible. - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 18,633,500,000 United States dollar | valid 2007-12-31 to 2008-12-31 | conf 0.95 | superseded | superseded_by [clm_F31DE382AAED](/claim/clm_F31DE382AAED.md) | [clm_6C192C099D33](/claim/clm_6C192C099D33.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 20,371,900,000 United States dollar | valid 2008-12-31 to 2009-12-31 | conf 0.95 | superseded | superseded_by [clm_75C93A8D0879](/claim/clm_75C93A8D0879.md) | [clm_F31DE382AAED](/claim/clm_F31DE382AAED.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 21,836,000,000 United States dollar | valid 2009-12-31 to 2010-12-31 | conf 0.95 | superseded | superseded_by [clm_2164E9BDD211](/claim/clm_2164E9BDD211.md) | [clm_75C93A8D0879](/claim/clm_75C93A8D0879.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 23,076,000,000 United States dollar | valid 2010-12-31 to 2011-12-31 | conf 0.95 | superseded | superseded_by [clm_BF9624252D1F](/claim/clm_BF9624252D1F.md) | [clm_2164E9BDD211](/claim/clm_2164E9BDD211.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000119312511041620/0001193125-11-041620-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 24,286,500,000 United States dollar | valid 2011-12-31 to 2012-12-31 | conf 0.95 | superseded | superseded_by [clm_8E230B90B165](/claim/clm_8E230B90B165.md) | [clm_BF9624252D1F](/claim/clm_BF9624252D1F.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000119312512078393/0001193125-12-078393-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 22,603,400,000 United States dollar | valid 2012-12-31 to 2013-12-31 | conf 0.95 | superseded | superseded_by [clm_8F9AC59BE835](/claim/clm_8F9AC59BE835.md) | [clm_8E230B90B165](/claim/clm_8E230B90B165.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947813000007/0000059478-13-000007-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 23,113,100,000 United States dollar | valid 2013-12-31 to 2014-12-31 | conf 0.95 | superseded | superseded_by [clm_931AAE69B168](/claim/clm_931AAE69B168.md) | [clm_8F9AC59BE835](/claim/clm_8F9AC59BE835.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/0000059478-14-000078-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 19,615,600,000 United States dollar | valid 2014-12-31 to 2015-12-31 | conf 0.95 | superseded | superseded_by [clm_53995054E4D5](/claim/clm_53995054E4D5.md) | [clm_931AAE69B168](/claim/clm_931AAE69B168.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947815000100/0000059478-15-000100-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 19,958,700,000 United States dollar | valid 2015-12-31 to 2016-12-31 | conf 0.95 | superseded | superseded_by [clm_09B0FB69C967](/claim/clm_09B0FB69C967.md) | [clm_53995054E4D5](/claim/clm_53995054E4D5.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947816000321/0000059478-16-000321-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 21,222,100,000 United States dollar | valid 2016-12-31 to 2017-12-31 | conf 0.95 | superseded | superseded_by [clm_0C495BD0FBE4](/claim/clm_0C495BD0FBE4.md) | [clm_09B0FB69C967](/claim/clm_09B0FB69C967.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947817000098/0000059478-17-000098-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 22,871,300,000 United States dollar | valid 2017-12-31 to 2018-12-31 | conf 0.95 | superseded | superseded_by [clm_E02BDD0A70F8](/claim/clm_E02BDD0A70F8.md) | [clm_0C495BD0FBE4](/claim/clm_0C495BD0FBE4.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947818000089/0000059478-18-000089-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 24,555,700,000 United States dollar | valid 2018-12-31 to 2019-12-31 | conf 0.95 | superseded | superseded_by [clm_BF0371526002](/claim/clm_BF0371526002.md) | [clm_E02BDD0A70F8](/claim/clm_E02BDD0A70F8.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947819000082/0000059478-19-000082-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 22,319,500,000 United States dollar | valid 2019-12-31 to 2020-12-31 | conf 0.95 | superseded | superseded_by [clm_E172D4945A79](/claim/clm_E172D4945A79.md) | [clm_BF0371526002](/claim/clm_BF0371526002.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/0000059478-20-000057-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 24,539,800,000 United States dollar | valid 2020-12-31 to 2021-12-31 | conf 0.95 | superseded | superseded_by [clm_8786FF8AD12B](/claim/clm_8786FF8AD12B.md) | [clm_E172D4945A79](/claim/clm_E172D4945A79.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947821000083/0000059478-21-000083-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 28,318,400,000 United States dollar | valid 2021-12-31 to 2022-12-31 | conf 0.95 | superseded | superseded_by [clm_4020D18C1AAA](/claim/clm_4020D18C1AAA.md) | [clm_8786FF8AD12B](/claim/clm_8786FF8AD12B.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947822000068/0000059478-22-000068-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 28,541,400,000 United States dollar | valid 2022-12-31 to 2023-12-31 | conf 0.95 | superseded | superseded_by [clm_2151D2F15ED6](/claim/clm_2151D2F15ED6.md) | [clm_4020D18C1AAA](/claim/clm_4020D18C1AAA.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/0000059478-23-000082-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 34,124,100,000 United States dollar | valid 2023-12-31 to 2024-12-31 | conf 0.95 | superseded | superseded_by [clm_282E1F71B318](/claim/clm_282E1F71B318.md) | [clm_2151D2F15ED6](/claim/clm_2151D2F15ED6.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/0000059478-24-000065-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 45,042,700,000 United States dollar | valid 2024-12-31 to 2025-12-31 | conf 0.95 | superseded | superseded_by [clm_C4636B99C62B](/claim/clm_C4636B99C62B.md) | [clm_282E1F71B318](/claim/clm_282E1F71B318.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947825000067/0000059478-25-000067-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | revenue | 65,179,000,000 United States dollar | valid 2025-12-31 to present | conf 0.95 | valid | [clm_C4636B99C62B](/claim/clm_C4636B99C62B.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.htm ## What replaced what - $18.63 billion (2007-12-31 to 2008-12-31, [clm_6C192C099D33](/claim/clm_6C192C099D33.md)) was replaced by $20.37 billion from 2008-12-31 ([clm_F31DE382AAED](/claim/clm_F31DE382AAED.md)) - $20.37 billion (2008-12-31 to 2009-12-31, [clm_F31DE382AAED](/claim/clm_F31DE382AAED.md)) was replaced by $21.84 billion from 2009-12-31 ([clm_75C93A8D0879](/claim/clm_75C93A8D0879.md)) - $21.84 billion (2009-12-31 to 2010-12-31, [clm_75C93A8D0879](/claim/clm_75C93A8D0879.md)) was replaced by $23.08 billion from 2010-12-31 ([clm_2164E9BDD211](/claim/clm_2164E9BDD211.md)) - $23.08 billion (2010-12-31 to 2011-12-31, [clm_2164E9BDD211](/claim/clm_2164E9BDD211.md)) was replaced by $24.29 billion from 2011-12-31 ([clm_BF9624252D1F](/claim/clm_BF9624252D1F.md)) - $24.29 billion (2011-12-31 to 2012-12-31, [clm_BF9624252D1F](/claim/clm_BF9624252D1F.md)) was replaced by $22.6 billion from 2012-12-31 ([clm_8E230B90B165](/claim/clm_8E230B90B165.md)) - $22.6 billion (2012-12-31 to 2013-12-31, [clm_8E230B90B165](/claim/clm_8E230B90B165.md)) was replaced by $23.11 billion from 2013-12-31 ([clm_8F9AC59BE835](/claim/clm_8F9AC59BE835.md)) - $23.11 billion (2013-12-31 to 2014-12-31, [clm_8F9AC59BE835](/claim/clm_8F9AC59BE835.md)) was replaced by $19.62 billion from 2014-12-31 ([clm_931AAE69B168](/claim/clm_931AAE69B168.md)) - $19.62 billion (2014-12-31 to 2015-12-31, [clm_931AAE69B168](/claim/clm_931AAE69B168.md)) was replaced by $19.96 billion from 2015-12-31 ([clm_53995054E4D5](/claim/clm_53995054E4D5.md)) - $19.96 billion (2015-12-31 to 2016-12-31, [clm_53995054E4D5](/claim/clm_53995054E4D5.md)) was replaced by $21.22 billion from 2016-12-31 ([clm_09B0FB69C967](/claim/clm_09B0FB69C967.md)) - $21.22 billion (2016-12-31 to 2017-12-31, [clm_09B0FB69C967](/claim/clm_09B0FB69C967.md)) was replaced by $22.87 billion from 2017-12-31 ([clm_0C495BD0FBE4](/claim/clm_0C495BD0FBE4.md)) - $22.87 billion (2017-12-31 to 2018-12-31, [clm_0C495BD0FBE4](/claim/clm_0C495BD0FBE4.md)) was replaced by $24.56 billion from 2018-12-31 ([clm_E02BDD0A70F8](/claim/clm_E02BDD0A70F8.md)) - $24.56 billion (2018-12-31 to 2019-12-31, [clm_E02BDD0A70F8](/claim/clm_E02BDD0A70F8.md)) was replaced by $22.32 billion from 2019-12-31 ([clm_BF0371526002](/claim/clm_BF0371526002.md)) - $22.32 billion (2019-12-31 to 2020-12-31, [clm_BF0371526002](/claim/clm_BF0371526002.md)) was replaced by $24.54 billion from 2020-12-31 ([clm_E172D4945A79](/claim/clm_E172D4945A79.md)) - $24.54 billion (2020-12-31 to 2021-12-31, [clm_E172D4945A79](/claim/clm_E172D4945A79.md)) was replaced by $28.32 billion from 2021-12-31 ([clm_8786FF8AD12B](/claim/clm_8786FF8AD12B.md)) - $28.32 billion (2021-12-31 to 2022-12-31, [clm_8786FF8AD12B](/claim/clm_8786FF8AD12B.md)) was replaced by $28.54 billion from 2022-12-31 ([clm_4020D18C1AAA](/claim/clm_4020D18C1AAA.md)) - $28.54 billion (2022-12-31 to 2023-12-31, [clm_4020D18C1AAA](/claim/clm_4020D18C1AAA.md)) was replaced by $34.12 billion from 2023-12-31 ([clm_2151D2F15ED6](/claim/clm_2151D2F15ED6.md)) - $34.12 billion (2023-12-31 to 2024-12-31, [clm_2151D2F15ED6](/claim/clm_2151D2F15ED6.md)) was replaced by $45.04 billion from 2024-12-31 ([clm_282E1F71B318](/claim/clm_282E1F71B318.md)) - $45.04 billion (2024-12-31 to 2025-12-31, [clm_282E1F71B318](/claim/clm_282E1F71B318.md)) was replaced by $65.18 billion from 2025-12-31 ([clm_C4636B99C62B](/claim/clm_C4636B99C62B.md)) ## Questions this record answers ### What is Eli Lilly and Company's current revenue? The latest figure on the record is $24.4 billion for the quarter ended September 30, 2026, from a primary source (sec.gov). The latest full-year figure is $65.18 billion, dated December 31, 2025, from a primary source (sec.gov). The record asserts both as of November 9, 2026. ### What was Eli Lilly and Company's revenue for the quarter ended September 30, 2026? $24.4 billion for the quarter ended September 30, 2026, dated September 30, 2026, from a primary source (sec.gov) (status valid, confidence 0.95). ### When did Eli Lilly and Company's revenue last change? The latest value on the record is $65.18 billion, dated December 31, 2025; before it the record holds $45.04 billion, dated December 31, 2024 and closed on December 31, 2025. ### What was Eli Lilly and Company's revenue before $65.18 billion? $45.04 billion, valid from December 31, 2024 to December 31, 2025 (status superseded), from a primary source (sec.gov). ## Read on - This page: /record/eli-lilly/revenue (markdown: /record/eli-lilly/revenue.md) - Entity twin: /record/eli-lilly.md ยท timeline: /timelines/eli-lilly.md - Every company's revenue: /facts/revenue.md --- AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.